The data are from a study titled "Circulating [interleukin 6] IL-6, an early biomarker in [hormone receptor-positive] HR+, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors" led by Dr. Khandan Keyomarsi at the University of Texas MD Anderson Cancer Center. The data will be presented by Nicole Kettner, PhD, a postdoctoral researcher in Keyomarsi's laboratory.

These data showed that Tavrdi's TTI-101, signal transducer and activator of transcription (STAT)-3 blocker, overcame palbociclib (CDK 4/6 inhibitor) resistance in HR+, HER2-negative metastatic murine breast cancer models through upregulation of IL-6/STAT3, according to a press release by the company.